Published in final edited form as:

Biochemistry. 2013 August 20; 52(33): . doi:10.1021/bi400556e.

Structure of MRDI Explains its Dual Function as a Metabolic Enzyme and a Mediator of Cell Invasion

Paul D. Templeton[§], Elizabeth S. Litman[‡], Sandra I. Metzner[§], Natalie G. Ahn^{§,‡,†,*}, and Marcelo C. Sousa^{§,*}

[§]Department of Chemistry and Biochemistry, University of Colorado at Boulder, Boulder, CO 80309-0596

[‡]HHMI, University of Colorado at Boulder, Boulder, CO 80309-0596

[†]BioFrontiers Institute, University of Colorado at Boulder, Boulder, CO 80309-0596

Abstract

Metastatic melanoma is among the most intractable cancers to treat, where patients show resistance to therapy and limited survival time. A critical step in the development of metastatic melanoma is the acquisition of invasion and transition from thin to thick tumors on the skin, followed by invasion to lymph nodes. Prior studies have shown that metastatic melanoma is associated with dysregulation of RhoA and enhanced expression of a protein named “mediator of RhoA-dependent invasion (MRDI)”. Importantly, MRDI is a “moonlighting” enzyme, with two distinct functions in melanoma cells. First, MRDI acts as a methylthioribose-1-phosphate (MTR-1-P) isomerase, catalyzing a critical step in methionine salvage. Second, MRDI promotes and is necessary for melanoma cell invasion, independent of its catalytic activity. Here, we demonstrate that MtnA, a bacterial MTR-1-P isomerase, rescues the methionine salvage function of MRDI, but is unable to rescue its role in invasion. We then solve the crystal structure of MRDI to a resolution of 2.5 Å, in order to identify structural elements important for its invasion activity. We present this structure and its comparison with other MTR-1-P isomerases, and identify mutations within a region separate from the MTR-1-P binding site which interfere with invasion. Thus, structural elements in MRDI distal from the MTR-1-P catalytic site are responsible for the invasion phenotype.

Keywords

Methionine Salvage; Melanoma; Invasion; Moonlighting Enzymes; Methylthioribose-1-phosphate Isomerase

One of the most interesting outcomes emerging from the study of cellular proteomes is the identification of “moonlighting” proteins, which are proteins known to perform more than one function. Many examples involve metabolic enzymes which show separate roles in diverse processes, including gene expression, signal transduction, and chaperone function ^(1, 2). Aconitase is a classic example, in which this TCA cycle enzyme also

*Co-corresponding authors: Marcelo Sousa, Department of Chemistry and Biochemistry, University of Colorado at Boulder, Boulder, CO 80309-0596, Phone: 303 735-4341, marcelo.sousa@colorado.edu Natalie Ahn, Department of Chemistry and Biochemistry, University of Colorado at Boulder, Boulder, CO 80309-0596, Phone: 303 492-4799, natalie.ahn@colorado.edu.

SUPPORTING INFORMATION AVAILABLE: A sequence alignment of MRDI, B subtilis MtnA and S cerevisiae Ypr118w (Figure S1); a representative sample of the electron density map associated with the final MRDI model (Figure S2); a table with the primers used for cloning and mutagenesis; and three movies highlighting the surface features of MRDI and MtnA, are included as supporting information. This material is available free of charge via the Internet at <http://pubs.acs.org>.

functions as an iron-responsive binding protein (IREBP), repressing translation of transferrin and other iron feedback inhibited proteins by binding the 5'-untranslated region of their mRNAs⁽³⁾. Initially, the number of moonlighting proteins were few and anecdotal. But with the increased numbers of functional annotations for proteins, in part due to large scale screening results, the discovery rate for proteins associated with unexpected processes is increasing⁽¹⁾. Therefore, the one protein-one function assumption is rapidly changing, and perhaps with new databases and data mining studies, the existence of moonlighting proteins may be the rule, rather than the exception. However, in most cases, the mechanisms underlying moonlighting behavior remain unknown, lacking structural analyses that explain the molecular basis of how one protein can mediate vastly distinct cellular functions.

In studies of metastatic melanoma cells, functional proteomics was used to screen for proteins that responded to constitutive activation of the GTPase, RhoA. A previously uncharacterized gene, named "Mediator of RhoA-dependent Invasion (MRDI)", was identified based on its induction in response to RhoA, and its ability to promote RhoA-dependent cell invasion in three-dimensional collagen matrices⁽⁴⁾. RNA interference showed that the expression of MRDI was necessary to allow tyrosine phosphorylation of focal adhesion kinase (FAK), an event which promotes kinase activation and cell motility.

Sequence alignments revealed a similarity between human MRDI and bacterial methylthioribose-1-phosphate isomerases. These enzymes function in methionine salvage by converting the S-adenosylmethionine metabolite, methylthioribose-1-phosphate (MTR-1-P), into methylthioribulose-1-phosphate (MTRu-1-P), which is ultimately converted to methionine in the salvage pathway⁽⁴⁻⁶⁾. The catalytic activity of MRDI as a MTR-1-P isomerase was demonstrated *in vitro* using NMR to identify the product. Furthermore, catalytic activity was abolished by mutations of residues Cys168 and Asp248, strictly conserved in MTR-1-P isomerases. In human cells, siRNA depletion of MRDI, or mutation of its conserved Cys168 or Asp248 residues, abolished the ability of cells to grow in methionine-free media supplemented with methylthioadenosine (MTA), the metabolic precursor to MTR-1-P. This confirmed the primary role of MRDI in human cells as an MTR-1-P isomerase that mediates the methionine salvage pathway.

Although mutations at the Cys and Asp residues implicated in catalysis ablated MTR-1-P isomerase activity, neither affected invasion of cells within 3D spheroids encapsulated in collagen⁽⁴⁾. This revealed that MRDI has separate mechanisms for its metabolic and invasive functions, and can thus be classified as a protein with moonlighting role in RhoA-dependent invasion. The uncoupling between invasive function and catalysis suggested that invasion may be mediated by protein-protein interactions. Consistent with this hypothesis, MRDI was found localized at the leading edge of cells, overlapping NWASP and the site of actin polymerization, where its higher effective concentration might enable protein-protein interactions important for cell movement.

Interestingly, a protein originally characterized as an Apaf1 interacting protein which prevents hypoxia-induced apoptosis⁽⁷⁾ was recently identified as MTRu-1-P dehydratase, the next enzyme in the methionine salvage pathway following MTR-1-P isomerase^(8,9). These recent findings further illustrate the prevalence of dual roles in metabolic enzymes and suggest that protein-protein interactions may be a general, catalysis-independent mechanism for their moonlighting functions.

Here, we examined MRDI by X-ray crystallography, in order to analyze the structural basis for its dual function. The X-ray structure of the human protein solved to 2.5 Å reveals similarities to previous structures of bacterial and yeast MTR-1-P isomerases, with conserved residues found within an open conformation of the active site. Expression of the

bacterial enzyme in human cells depleted for MRDI enabled rescue of cell growth in the presence of MTA, but not cell invasion in collagen spheroids. Mutation of amino acids within a putative binding pocket unique to human MRDI resulted in inhibition of spheroid invasion. Together the results indicate that dual function of MRDI can be attributed to distinct protein regions, including a conserved catalytic site which is needed for metabolic activity, and a separate binding pocket, distal to the active site, which is responsible for RhoA-dependent cell invasion.

MATERIALS AND METHODS

Cloning and mutagenesis

Cloning, heterologous expression in *E. coli* and purification of MRDI were carried out as described ⁽⁴⁾. The human MRDI gene containing silent mutations to bypass the shRNA interference (bpWT) was subcloned into the plasmid pET41b+ for *E. coli* expression. This plasmid was then used to introduce all the point mutations used in this study, using the QuikChange^{TM}(Invitrogen) site directed mutagenesis protocol, using the mutagenic primers shown in Supplemental Table ST1. The mutations were confirmed by sequencing and subcloned, using NotI and SfiI restriction sites, into the pREX-MRDI bpWT plasmid ⁽⁴⁾ for retroviral expression in A375 cells. The genes for *B. subtilis* MtnA and *S. cerevisiae* Ypr118W were PCR-amplified from genomic DNA using the primers shown in Supplemental Table ST1. The C-terminal primers incorporated a hemagglutinin (HA) fusion tag at the C-termini of both genes. The amplified fragments were digested with EcoRI and NotI and ligated into the pREX vector digested with the same restriction enzymes. The correctness of the final products was confirmed by DNA sequencing.

Protein crystallization and X-ray data collection

Crystals of MRDI were grown in hanging drops at 16°C in a precipitant solution containing 0.7 M Na-citrate and 100 mM imidazole, pH 8.0. Crystals appeared overnight, but growth was allowed to continue for one week after which no additional growth was observed. For data collection, crystals were transferred to a cryo-protecting solution composed of 10% glycerol, 0.7 M Na-citrate, and 100 mM imidazole, pH = 8.0, and flash frozen in a nitrogen stream at 100 °K. Diffraction data were collected with a rotating anode generator using Cu K α radiation and a Rigaku R-Axis IV++ image plate detector placed such that the direct beam was centered on the detector (no detector swing). The crystal to detector distance was set at 200 mm and 130 degrees of data collected in 0.5 degree oscillations. The crystals belonged to space group P2₁2₁2₁, with unit cell dimensions a = 44.8, b = 116.5, c = 137.9 Å and $\alpha = \beta = \gamma = 90^\circ$.

Crystals of MRDI Ser283Tyr were grown under conditions similar to those of the wild type protein. The crystals were frozen as described above and diffraction data collected at beamline 5.0.2 of the Advanced Light Source, Lawrence Berkeley National Laboratories. Radiation wavelength was set to 1Å and an ADSC CCD detector placed 250 mm from the crystal (no detector swing). Analysis of preliminary diffraction images with Mosflm ^(10, 11) confirmed that the lattice of the mutant protein crystal was similar to that of the wild type, and allowed development of a collection strategy to maximize data completeness and redundancy while minimizing total exposure. Based on these estimates, 100 degrees of data were collected in 1 degree oscillations. Data reduction for both crystals was carried out in HKL2000 ⁽¹²⁾ and data collection statistics are summarized in Table 1.

Structure determination and refinement

A sequence similarity search of the Protein Data Bank using BLAST revealed a protein annotated as eIF2B from *Leishmania major* (PDB ID 2A0U, Bosch, J. and Hol, W.,

unpublished results) sharing 45% sequence identity with MRDI, suggesting that this protein could be used as a model to determine the MRDI structure by molecular replacement. To maximize the similarity between the model and MRDI, we used the program Chainsaw⁽¹³⁾ to prune non-conserved residues to the gamma carbon while conserved residues were left intact. The *Leishmania* protein was a dimer in the crystallographic asymmetric unit. We used the dimer as a search model, as analysis of the MRDI crystal lattice contents suggested the presence of two monomers per asymmetric unit. Rotation/translation searches with the program Phaser⁽¹⁴⁾ using data to 2.5 Å resolution yielded a clear solution without significant packing clashes. Using the program CNS⁽¹⁵⁾, the model was subjected to one round of refinement and an electron density map was calculated to 2.5 Å resolution. Several amino acid side chains missing from the model were readily observed in the electron density map, validating the correctness of the molecular replacement solution. The model was rebuilt using the programs O⁽¹⁶⁾ and Coot⁽¹⁷⁾, and alternative rounds of refinement and rebuilding were performed until no further improvement of the R-factors was achieved. The structure of MRDI Ser283Tyr was determined using the MRDI structure as a starting model where Ser283 was mutated to Ala, all water molecules were removed, and all B factors randomized. The model was then subjected to rigid body refinement followed by rebuilding and positional and B-factor refinement in PHENIX⁽¹⁸⁾. Final refinement statistics are summarized in Table 1.

Cell culture and Western blotting

A375 melanoma cell lines were obtained from ATCC and maintained in 10% FBS-RPMI. Cells with stable shRNA knockdown of MRDI were treated to stably express WT or mutant MRDI, or the MTR-1-P isomerase, (HA tagged)-MtnA from *B. subtilis*, using retroviral delivery as described⁽⁴⁾. Expression was confirmed by Western blotting using anti-MRDI polyclonal antibodies obtained by immunization of rabbits with a synthetic peptide corresponding to aminoacids 356-369 of human MRDI (TISSRDGTLDGPQM; Sigma-Genosys); or rabbit anti-HA antibodies (HA.11, Covance) as primary antibodies. Secondary anti-rabbit or anti-mouse antibodies coupled to horseradish peroxidase (Jackson ImmunoResearch Laboratories) and enhanced chemiluminescence substrates (Amersham) recorded on film were then used to visualize immunoreactive bands.

Cell proliferation and invasion assays

Assays for rescue of cell viability by MTR-1-P isomerase expression were conducted by plating cells in duplicate into 6 well chambers (100,000 cells /well) with 3 mL RPMI + 10% FBS. After overnight incubation to allow cell adhesion, the media was replaced with 3 mL methionine-free RPMI + 10% dialyzed FBS, supplemented with or without methylthioadenosine (30 µM) or methionine (15 mg/mL). After 96 h, cells were trypsinized and counted in trypan blue using a hemocytometer. Cell counts were obtained by averaging values from four replicate measurements made from each of the duplicate wells. Spheroid cell invasion assays were carried out as described^(19, 20). Briefly, 25,000 melanoma cells were plated in triplicate into 6 well plates containing 1.5% Noble agar, in RPMI-10% FBS. After 3-5 days, spheroids were collected by centrifugation, resuspended into 2.5 mg/mL collagen, and overlaid on a pre-solidified layer of the same collagen solution. Images of spheroids were collected 4 days after implantation, using an Olympus IX81 microscope equipped with a DP70-CCD camera for phase microscopy. Spheroid growth was quantified by measuring the diameter of the inner core of cells (in mm), and cell invasion measured the outer radius of cells invading into collagen minus the inner radius. For each spheroid, the radii along 4-8 axes were measured and averaged.

RESULTS

Distinct properties of MTR-1-P isomerases from human and bacteria

Our previous study established the catalytic activity of MRDI as a MTR-1-P isomerase (3). Deletion of MRDI from human cells or mutation of conserved residues Cys168 or Asp248 abolished the ability of human cells to grow in methionine-free media supplemented with methylthioadenosine (MTA) as a source of methionine produced by the salvage pathway. Orthologous MTR-1-P isomerases have been reported to function in methionine salvage ^(21, 22). *B. subtilis* MtnA shares 39% sequence identity with MRDI (Supplementary Fig. S1). Its MTR-1-P isomerase activity has been verified *in vitro*, and its structure in complex with product MTRu-1-P has been reported ⁽²²⁾.

To test whether *B. subtilis* MtnA was able to substitute for MRDI in human cells with respect to methionine salvage and/or invasion, we stably expressed HA-tagged MtnA in melanoma cells that were depleted of MRDI using shRNA. MtnA expression had little effect on cells growing in complete media (Fig. 1A). However, whereas cells depleted of MRDI started to die after 48 hours in methionine-free media supplemented with MTA, expression of MtnA in these cells supported continued growth to approximately 90% of the wild type cell levels (Fig. 1B). This indicates that the bacterial orthologue rescues the loss of MRDI with respect to its methionine salvage function. By comparison, overexpression of an MRDI variant containing silent cDNA mutations, which bypasses shRNA but yields a WT protein sequence (“bpWT”) supported more robust growth in methionine-free media containing MTA, to approximately 200% of wild type levels.

To test whether MtnA could also support the cell invasion phenotype, cells depleted of MRDI and expressing MtnA were grown as 3D spheroids implanted into collagen. MtnA failed to increase cell invasion over levels observed in MRDI-depleted cells (Fig. 1C-D), whereas expression of recombinant MRDI-bpWT readily reversed the invasion phenotype. Thus, the bacterial ortholog shared MRDI’s function as a metabolic enzyme, but lacked its function as a mediator of cell invasion.

Crystal structure of human MRDI

In order to better understand the unique features that distinguish MRDI from the bacterial MTR-1-P isomerase, the protein was crystallized and its 3D structure determined (Fig. 2A). As detailed in Materials and Methods, the structure was determined by molecular replacement using a homologous structure from *Leishmania major* (PDB ID 2A0U, Bosch, J. and Hol, W. unpublished results) as the search model, and refined to 2.5Å resolution. MRDI is a dimer in solution as determined by size exclusion chromatography (data not shown) and the crystallographic asymmetric unit contains one MRDI dimer. The final model contains all residues except the N-terminal methionine in each subunit and the last 15 amino acids (the last 12 on chain B) presumably due to conformational flexibility. The final model had an R-value = 0.178 and R_{free} = 0.211 with excellent stereochemistry and 97.4% of non-glycine residues in the most favored regions of the Ramachandran plot. Two flexible loops in the N-terminus (residues 66-72 and 113-117) display high B-factors (Fig. 2B). Leu72 residues lie within the 66-72 loop of each chain and represent the only two residues that refine as Ramachandran outliers, likely due to conformational flexibility. Data collection and refinement statistics are summarized in Table 1, and a representative piece of the electron density is shown in Supplementary Fig. S2.

The individual subunits have essentially identical conformations, with RMSD = 0.5 Å for all 353 C atoms common to both protomers. Each monomer contains two distinct domains. The N-terminal domain is arranged in a five-helix bundle and a three stranded β -sheet (red and blue, Fig. 2A) whereas the C-terminal domain forms a Rossmann-like fold (orange and

green, Fig. 2A) and includes a dimerization interface which buries approximately 4,720 Å² of surface area. A long α -helix provides the connection between the two domains (Fig. 2A). The N-terminal domains of both chains have higher temperature factors than the C-terminal domains, possibly reflecting flexibility on the connecting α -helix (Fig. 2B). A deep cleft between N- and C-terminal domains forms the active site containing catalytic residues Cys168 and Asp248 (Fig. 2A, shown as space filling models). Sequence alignment revealed strong conservation of the residues lining the active site cleft, but significant divergence among the surface exposed residues (Fig. 2C, D).

An open-closed conformational change in MTR-1-P isomerases

The structure of MtnA was determined with the MTRu-1-P product bound in its active site ⁽²²⁾. Comparison of this structure to MRDI reveals a striking conformational difference, where the N-terminal domain of MtnA is rotated approximately 30 degrees (estimated with Dyn Dom ⁽²³⁾) and collapsed on top of the C-terminal domain, closing the active site cleft around the ligand (Fig. 3A, B). Therefore, MRDI adopts an open conformation of the enzyme, while MtnA in complex with MTRu-1-P adopts a closed conformation, as previously hypothesized by Tamura et al. ⁽²²⁾. To test the feasibility of this conformational change, we separated the N- and C-terminal domains of MtnA and superimposed them independently onto the N- and C-terminal domains of MRDI. The results showed excellent agreement between the two structures, without significant clashes. Similarly, the N and C-terminal domains could be superimposed onto the MtnA structure without major clashes, suggesting that an open-to-closed transition is feasible in these MTR-1-P isomerases. The apparent flexibility of the α -helix that connects the N and C-terminal domains (Fig 2B) is also consistent with this conformational change as the transition is mediated by bending of this α -helix.

In addition to the catalytic residues Cys168 and Asp248, all residues that were identified in MtnA as important for ligand binding ⁽²⁴⁾ were strictly conserved in MRDI. These included Arg46-Pro49 and Arg90-Thr92 in the N-terminal domain, and Ala174, Thr175, Gln207, Asn258, Lys259 and Phe325 in the C-terminal domain. Figure 3C shows a superposition of the conserved active site residues in MRDI (dark green) and ligand-bound MtnA (light green and gray side chains), which illustrates the rearrangement of the N-terminal domain ligand binding residues (Arg46, Arg90 and Thr92) due to the open-to-closed transition. A possible reaction mechanism for the isomerization reaction is shown in Fig 3D. In this scheme, the deprotonated side chain of Cys168 abstracts a proton from C2, while Asp248 donates a proton to the furanose oxygen to promote ring opening with formation of a double bond between C1 and C2. Proton transfer from the O2 of the enediol intermediate to Asp 248, and from the protonated side chain of Cys168 to C1 forms the product MTRu-1-P and regenerates the initial state of the enzyme. A similar mechanism was proposed by Tamura and coworkers, although an additional hydride transfer alternative was also proposed ⁽²²⁾.

Divergent features in MRDI identify a potential binding site controlling invasion

In MRDI, the isomerase catalytic function is uncoupled from the invasion function, as demonstrated by the ability of catalytically inactive MRDI mutants to support invasion. Given that MtnA was also unable to support the invasion phenotype (Fig. 1C), we speculated that the invasion function might involve protein-protein interactions within regions distinct from the catalytic site, which is also the region showing highest conservation of surface residues (Fig. 2C, D). MRDI was thus inspected for surface residues that were not conserved between the two isomerases, as well as surface features unique to MRDI, in order to identify potential binding regions for protein effectors of invasion. Comparison of the surface features of MRDI and MtnA modeled in the open conformation (most similar to MRDI) identified a distinctive cavity in MRDI, located on the concave face

of opposite to the active site cleft, lined with a patch of surface exposed hydrophobic residues (Fig. 4A, Supplementary Movie 1). In contrast, the corresponding surface in MtnA was shallower and lined with charged residues (Fig. 4B, Supplementary Movie 2).

In order to test the importance of this surface, single mutations to Ala were introduced, replacing non-conserved residues Arg98, Arg101 and Arg109 in MRDI. In addition, Glu and Trp mutations of Ser282 and Tyr mutations of Ser283, located in the center of this pocket, were constructed with the hypothesis that larger side chains might disrupt potential binding to this interface. Modeling of the mutant side chains on MRDI showed that multiple common rotamers could be accommodated without clashes. Therefore, the mutations were not expected to interfere with the correct folding of MRDI.

WT and mutant MRDI cDNA were stably expressed in cells depleted for endogenous MRDI by shRNA knockdown, and cells were assayed for spheroid invasion in collagen. Little or no difference was observed between expression of bpWT MRDI and the mutants with respect to the ability of cells to proliferate, as measured by the spheroid growth. However, when collagen cell invasion was quantified by the difference between the outer radius representing the furthest extent of cell migration and the inner radius of the compacted spheroid, MRDI mutants Arg109Ala and Ser283Tyr showed suppression (Fig. 5A,B), comparable to the levels observed in the MRDI shRNA knockdown condition. Western blotting confirmed that the expression levels of all MRDI mutants were comparable to the expression of bpWT (Fig. 5C). In addition, we determined the crystal structure of MRDI-Ser283Tyr in order to rigorously rule out the possibility that impaired invasion might be caused by folding defects introduced by the Ser283Tyr mutation. The mutant structure was essentially identical to that of WT-MRDI, with an RMSD of 0.2 Å for all 356 C^α carbons. The only significant difference was the expected protuberance produced by the large tyrosine side chain within the cavity (Fig. 4C, Supplementary Movie 3). Hence, rescue of invasion could be blocked by a mutation in MRDI (Ser283Tyr) that disrupted the geometry of the proposed binding pocket, and another mutation (Arg109Ala) which removed a basic surface charge. We propose that these mutations define a binding pocket which functions to mediate interactions between MRDI and as yet unknown cellular effectors of invasion.

DISCUSSION

MRDI was initially identified as a gene product elevated in response to constitutively activated RhoA-GTP in cell lines derived from human melanoma metastases⁽⁴⁾. MRDI regulates tyrosine phosphorylation of focal adhesion kinase and modulates cell invasion in melanoma cells, and for this reason it was named Mediator of RhoA Dependent Invasion (MRDI). Based on its similarity with known isomerases, MRDI was shown to catalyze the conversion of methylthioribose-1-phosphate (MTR-1-P) to methylthioribulose-1-phosphate (MTRu-1-P), an important reaction in methionine salvage pathway. Consistent with this role, MRDI was required for cells to grow in methionine-free media supplemented with MTA, the metabolic precursor to MTR-1-P that is eventually converted to methionine. Mutation of residues Cys168 and Asp248 abolished MRDI's isomerase activity and its ability to support growth in methionine-free, MTA-supplemented media. However, its ability to mediate the invasion phenotype in melanoma-derived cell was unaffected. This indicated that the “moonlighting” role of MRDI as a regulator of cell invasion evolved from a protein with enzymatic function in amino acid metabolism.

Our work defines the structural features in MRDI that mediate its distinct function in invasion. The structure of MRDI shows a high degree of similarity with known MTR-1-P isomerases, such as *B. subtilis* MtnA and *S. cerevisiae* Ypr118w^(21, 22). These dimeric proteins have N and C-terminal domains linked through a long α -helix and an active site

cleft defined by the interface between the two domains. MtnA rescued methionine salvage in cells depleted of MRDI by shRNA, indicating that the isomerase function in methionine salvage appears ancient. (Analogous rescue experiments could not be conducted with yeast Ypr118W because the protein expressed poorly in A375 cells, Fig. 5C). This is consistent with the MRDI structure, which showed high conservation of not only the catalytic residues, but also the residues lining the entire active site cleft (Figs. 2C,D and 3C). However, despite structural similarity with MRDI, MtnA when expressed in A375 melanoma cells was incapable of supporting the invasion phenotype (Fig. 1). Therefore we conclude that the invasion phenotype is unrelated to the conserved active site residue and unique to the human MRDI.

Comparison of the MRDI structure with that of product (MTRu-1-P) bound MtnA revealed two distinct conformations, consistent with a proposed domain closure in MTR-1-P isomerases⁽²²⁾. Ligand-free MRDI represents an open conformation, where the active site cleft is solvent exposed. Conversely, product-bound MtnA represents a closed conformation, where the N- and C-terminal domains collapse around the ligand closing the active site cleft (Fig. 3A-C). Interestingly, the structure reported for apo-MtnA also formed a closed conformation in absence of ligand⁽²²⁾. However, this protein was crystallized from ammonium sulfate, and a sulfate ion was found in the same position occupied by the phosphate from MTRu-1-P in the liganded structure. Similarly, the yeast ortholog Ypr118w, was also crystallized from ammonium sulfate and the structure formed the closed conformation containing a sulfate ion in the active site⁽²¹⁾. This suggests that coordination of the substrate phosphate (or sulfate at high concentrations) is enough to induce domain closure.

MTR-1-P isomerases including MRDI are part of a superfamily related by sequence to α and β subunits of the eukaryotic translation initiation factor 2B (eIF2B). eIF2B is a heteropentameric complex which functions as the guanine nucleotide exchange factor (GEF) for the G-protein “eukaryotic initiator factor 2” (eIF2) and promotes translational initiation^(5, 25). However, the GEF activity of eIF2B depends on its catalytic α subunits whereas the roles of the β , γ , and δ subunits are unclear but appear to modulate the activity of the catalytic subunits. In the structure of eIF2B α , Hiyama and coworkers described a deep basic pocket at the interface between the N- and C-terminal domains⁽²⁶⁾. The authors propose that this pocket represents a docking site for a phosphate group which allows eIF2B to recognize eIF2 phosphorylated at Ser51⁽²⁷⁾ by various upstream kinases, such as GCN2, PERK, PKR and HRI. Analogous to the structures of *S. cerevisiae* Ypr118w and *B. subtilis* MtnA, the structure of eIF2B α was solved with a sulfate ion co-crystallized in this basic pocket. eIF2B α residues coordinating the sulfate ion were Arg108, Ser131, Arg132, Ala197, Asp208, and Glu231. If MRDI were a viable subunit substitute for eIF2B subunits, we would expect these residues to be conserved. However, a structure-based sequence alignment of MRDI with eIF2B α performed with Dali⁽²⁸⁾ show that only the residues corresponding to Ala197 and Asp 208 in MRDI were conserved. Thus it is unlikely that the moonlighting, invasion function of MRDI is associated with a role in translational initiation. An alternative possibility is that phosphorylated effector proteins might be recognized by the negatively charged active site groove in MRDI, analogous to the recognition of phospho-eIF2 by eIF2B. However, this would have predicted that MtnA, which retained the negatively charged active site groove, should have supported the invasion phenotype, which was not observed.

Therefore, MRDI is part of an evolutionary progression which connects protein synthesis, amino acid metabolism, and signal transduction. Structurally, MRDI and MtnA are part of the eIF2B superfamily, but are functionally distinct from the translational regulators and instead share MTR-1-P isomerase activity. The human MRDI represents a new branch

distinct from bacterial and yeast orthologues, by acquiring a unique function in signal dependent cell invasion.

We considered whether the role of MRDI in invasion might involve a separate region involving non-conserved surface features unique to MRDI, which could for example serve as a binding site for interactions with other protein effectors. To facilitate the search for such structural features, we modeled MtnA in an open conformation similar to that of MRDI. A cavity unique to MRDI was identified, lined by a large hydrophobic patch on a concave surface, opposite to each active site cleft in MRDI (Fig. 4). Given that protein-protein interaction interfaces are typically enriched in hydrophobic residues ⁽²⁹⁾, we tested the possibility that this interface might be associated with the unique invasive function of MRDI. If our hypothesis were correct, we expected that replacing a small side chain with a large bulky residue would have a dramatic effect on blocking binding interactions, due to steric hindrance. Consistent with this hypothesis, the Ser283Tyr mutation introduced a large protuberance in the concave surface (Fig. 4C), coupled to an inability to rescue invasion (Fig. 5). On the other hand, Ser282Trp and Ser282Glu had no effect on the invasion phenotype. However, modeling indicated that some allowed rotamers of these mutants would have little impact on the interface geometry.

We also tested the importance of specific surface-exposed residues which were also unique to MRDI. Mutation of non-conserved Arg residues revealed the importance of Arg109 in invasion. Taken together, these results support the conclusion that the invasion phenotype is independent of catalysis, and may instead be controlled by interactions between MRDI and other proteins through sites on the dimer outside the active sites.

There is precedent for enzymes evolving moonlighting functions that require binding sites distal from the active site. For example, *Hansenula polymorpha* pyruvate carboxylase was shown to moonlight as an assembly factor for alcohol oxidase and mediate its import into the peroxisome ⁽³⁰⁾. While the active site of pyruvate carboxylase is located at the C-terminal side of the α -strands that make up its TIM barrel structure, the residues required for the moonlighting activity are clustered on the opposite, N-terminal side of the α -strands in the TIM barrel ⁽³⁰⁾. Proteins without catalytic activities can also develop moonlighting roles involving distinct binding sites in the protein. One such case is illustrated by tumor necrosis factor whose receptor-binding domain promotes an inflammatory response. However, residues distant from the receptor binding site that map to the lectin-like domain mediate non-cytokine effects of tumor necrosis factor, such as lysis of trypanosomes ⁽³¹⁾ and protection against pulmonary edema ^(32, 33). It is fascinating that MTRu-1-P dehydratase, the next enzyme following MRDI in the methionine salvage pathway, also has moonlighting function as an anti-apoptotic protein through its Apaf-1 binding activity ^(8,9). MTA phosphorylase, the enzyme immediately preceding MRDI in methionine salvage, also functions as a tumor suppressor gene, although it is possible that this may be due to its enzymatic role in methionine salvage, by depleting cellular levels of MTA ⁽³⁴⁾. Our findings, which now map the catalytic and invasion-related functions of MRDI to distinct regions of the structure, contribute to the growing evidence that moonlighting proteins have greater prevalence as well as an expanded importance in cell physiology than initially appreciated ^(1, 35).

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We are indebted to Theresa Nahreini for assistance with cell culture, and to Steven Edwards and David McKay for X-ray facility support.

Funding Sources: This work was supported by NIH grants R01 CA118972 (Ahn), and T32 GM008759 (Templeton). Structural biology research at the University of Colorado, Boulder is supported in part by the William M. Keck Foundation. Part of the work presented in this manuscript was carried out at The Advanced Light Source, which is supported by the Director, Office of Science, Office of Basic Energy Sciences, of the U.S. Department of Energy under Contract No. DE-AC02-05CH11231.

Abbreviations

MRDI	Mediator of RhoA Dependent Invasion
MTR-1-P	methylthioribose-1-phosphate
MTRu-1-P	methylthioribulose-1-phosphate
MTA	methylthioadenosine
KD	knockdown
bpWT	wild-type MRDI containing silent mutations which bypass shRNA
eIF2B	eukaryotic initiation Factor 2B
HA	hemagglutinin
FBS	fetal bovine serum

REFERENCES

1. Copley SD. Moonlighting is mainstream: paradigm adjustment required. *Bioessays*. 2012; 34:578–588. [PubMed: 22696112]
2. Jeffery CJ. Moonlighting proteins: old proteins learning new tricks. *Trends Genet*. 2003; 19:415–417. [PubMed: 12902157]
3. Rouault TA. The role of iron regulatory proteins in mammalian iron homeostasis and disease. *Nat Chem Biol*. 2006; 2:406–414. [PubMed: 16850017]
4. Kabuyama Y, Litman ES, Templeton PD, Metzner SI, Witze ES, Argast GM, Langer SJ, Polvinen K, Shellman Y, Chan D, Shabb JB, Fitzpatrick JE, Resing KA, Sousa MC, Ahn NG. A mediator of Rho-dependent invasion moonlights as a methionine salvage enzyme. *Mol Cell Proteomics*. 2009; 8:2308–2320. [PubMed: 19620624]
5. Kyrpides NC, Woese CR. Archaeal translation initiation revisited: the initiation factor 2 and eukaryotic initiation factor 2B alpha-beta-delta subunit families. *Proc. Natl. Acad. Sci. USA*. 1998; 95:3726–3730. [PubMed: 9520434]
6. Pirkov I, Norbeck J, Gustafsson L, Albers E. A complete inventory of all enzymes in the eukaryotic methionine salvage pathway. *FEBS J*. 2008; 275:4111–4120. [PubMed: 18625006]
7. Cho DH, Hong YM, Lee HJ, Woo HN, Pyo JO, Mak TW, Jung YK. Induced inhibition of ischemic/hypoxic injury by APIP, a novel Apaf-1-interacting protein. *J. Biol. Chem*. 2004; 279:39942–39950. [PubMed: 15262985]
8. Ko DC, Gamazon ER, Shukla KP, Pfuetzner RA, Whittington D, Holden TD, Brittnacher MJ, Fong C, Radey M, Ogohara C, Stark AL, Akey JM, Dolan ME, Wurfel MM, Miller SI. Functional genetic screen of human diversity reveals that a methionine salvage enzyme regulates inflammatory cell death. *Proc. Natl. Acad. Sci. USA*. 2012; 109:E2343–2352. [PubMed: 22837397]
9. Mary C, Duek P, Salleron L, Tienz P, Bumann D, Bairoch A, Lane L. Functional identification of APIP as human mtnB, a key enzyme in the methionine salvage pathway. *PLoS One*. 2012; 7:e52877. [PubMed: 23285211]

10. Battye TG, Kontogiannis L, Johnson O, Powell HR, Leslie AG. iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM. *Acta Crystallogr.* 2011; 67:271–281.
11. Leslie AG. The integration of macromolecular diffraction data. *Acta Crystallogr.* 2006; 62:48–57.
12. Otwinowski Z, Minor W. Processing of X-ray diffraction data collected in oscillation mode. *Methods Enzym.* 1997; 276:307–326.
13. Stein N. CHAINSAW: a program for mutating pdb files used as templates in molecular replacement. *J. Appl. Cryst.* 2008; 41:641–643.
14. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ. Phaser crystallographic software. *J. Appl. Cryst.* 2007; 40:658–674. [PubMed: 19461840]
15. Brünger AT, Adams PD, Clore GM, DeLano WL, Gros P, Grosse-Kunstleve RW, Jiang JS, Kuszewski J, Nilges M, Pannu NS, Read RJ, Rice LM, Simonson T, Warren GL. Crystallography & NMR system: A new software suite for macromolecular structure determination. *Acta Crystallogr.* 1998; 54:905–921.
16. Jones A. A Graphics Model Building and Refinement System for Macromolecules. *J. Appl. Cryst.* 1978; 11:268–272.
17. Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. *Acta Crystallogr.* 2004; 60:2126–2132.
18. Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, Echols N, Headd JJ, Hung LW, Kapral GJ, Grosse-Kunstleve RW, McCoy AJ, Moriarty NW, Oeffner R, Read RJ, Richardson DC, Richardson JS, Terwilliger TC, Zwart PH. PHENIX: a comprehensive Python-based system for macromolecular structure solution. *Acta Crystallogr.* 2010; 66:213–221.
19. Argast GM, Croy CH, Coutts KL, Zhang Z, Litman E, Chan DC, Ahn NG. Plexin B1 is repressed by oncogenic B-Raf signaling and functions as a tumor suppressor in melanoma cells. *Oncogene.* 2009; 28:2697–2709. [PubMed: 19483722]
20. Smalley KS, Haass NK, Brafford PA, Lioni M, Flaherty KT, Herlyn M. Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. *Mol. Cancer Ther.* 2006; 5:1136–1144. [PubMed: 16731745]
21. Bumann M, Djafarzadeh S, Oberholzer AE, Bigler P, Altmann M, Trachsel H, Baumann U. Crystal structure of yeast Ypr118w, a methylthioribose-1-phosphate isomerase related to regulatory eIF2B subunits. *J. Biol. Chem.* 2004; 279:37087–37094. [PubMed: 15215245]
22. Tamura H, Saito Y, Ashida H, Inoue T, Kai Y, Yokota A, Matsumura H. Crystal structure of 5-methylthioribose 1-phosphate isomerase product complex from *Bacillus subtilis*: implications for catalytic mechanism. *Prot. Sci.* 2008; 17:126–135.
23. Hayward S, Berendsen HJ. Systematic analysis of domain motions in proteins from conformational change: new results on citrate synthase and T4 lysozyme. *Proteins.* 1998; 30:144–154. [PubMed: 9489922]
24. Tamura K, Nei M, Kumar S. Prospects for inferring very large phylogenies by using the neighbor-joining method. *Proc. Natl. Acad. Sci. USA.* 2004; 101:11030–11035. [PubMed: 15258291]
25. Mohammad-Qureshi SS, Jennings MD, Pavitt GD. Clues to the mechanism of action of eIF2B, the guanine-nucleotide-exchange factor for translation initiation. *Biochem Soc Trans.* 2008; 36:658–664. [PubMed: 18631136]
26. Hiyama TB, Ito T, Imataka H, Yokoyama S. Crystal structure of the alpha subunit of human translation initiation factor 2B. *J. Mol. Biol.* 2009; 392:937–951. [PubMed: 19631657]
27. Pavitt GD, Ramaiah KV, Kimball SR, Hinnebusch AG. eIF2 independently binds two distinct eIF2B subcomplexes that catalyze and regulate guanine-nucleotide exchange. *Genes Dev.* 1998; 12:514–526. [PubMed: 9472020]
28. Holm L, Kaariainen S, Rosenstrom P, Schenkel A. Searching protein structure databases with DaliLite v.3. *Bioinformatics.* 2008; 24:2780–2781. [PubMed: 18818215]
29. Gruber J, Zawaira A, Saunders R, Barrett CP, Noble ME. Computational analyses of the surface properties of protein-protein interfaces. *Acta Crystallogr.* 2007; 63:50–57.
30. Huberts DH, Venselaar H, Vriend G, Veenhuis M, van der Klei IJ. The moonlighting function of pyruvate carboxylase resides in the non-catalytic end of the TIM barrel. *Biochim. Biophys. Acta.* 2010; 1803:1038–1042. [PubMed: 20359504]

31. Lucas R, Magez S, De Leys R, Fransen L, Scheerlinck JP, Rampelberg M, Sablon E, De Baetselier P. Mapping the lectin-like activity of tumor necrosis factor. *Science*. 1994; 263:814–817. [PubMed: 8303299]
32. Hundsberger H, Verin A, Wiesner C, Pfluger M, Dulebo A, Schutt W, Lasters I, Mannel DN, Wendel A, Lucas R. TNF: a moonlighting protein at the interface between cancer and infection. *Front. Biosci.* 2008; 13:5374–5386. [PubMed: 18508593]
33. Yang G, Hamacher J, Gorshkov B, White R, Sridhar S, Verin A, Chakraborty T, Lucas R. The Dual Role of TNF in Pulmonary Edema. *J. Cardiovas. Dis. Res.* 2010; 1:29–36.
34. Christopher SA, Diegelman P, Porter CW, Kruger WD. Methylthioadenosine phosphorylase, a gene frequently codeleted with p16(cdkN2a/ARF), acts as a tumor suppressor in a breast cancer cell line. *Cancer Res.* 2002; 62:6639–6644. [PubMed: 12438261]
35. Huberts DH, van der Klei IJ. Moonlighting proteins: an intriguing mode of multitasking. *Biochim. Biophys. Acta.* 2010; 1803:520–525. [PubMed: 20144902]
36. Kyte J, Doolittle RF. A simple method for displaying the hydropathic character of a protein. *J. Mol. Biol.* 1982; 157:105–132. [PubMed: 7108955]

Fig. 1. Phenotypes of MRDI and MtnA expression and deletion

(A) Growth in full media of A375 melanoma cells, carrying empty vector (Vector), depleted of MRDI with shRNA (KD), depleted of endogenous MRDI and expressing a wild-type bypass MRDI (bpWT), or depleted of endogenous MRDI and expressing *B. subtilis* MtnA (MtnA). The bars represent cell counts for time 0, 48 and 96 hours normalized to that of cells carrying empty vector at time = 0h. (B) Same as (A) but with cells grown in methionine-free media supplemented with 30 μ M MTA. (C) Quantitation of cell invasiveness in 3D spheroid assays carried as described in Materials and Methods. Values represent the mean of 10-11 independent experiments. The error bars represent standard deviation of the mean. (D) Representative images of 3D spheroid invasion assays, for cells quantified in (C).

Fig. 2. X-ray structure of MRDI

(A) “Side” view of the MRDI dimer, with N-terminal domains colored red and blue and C-terminal domains colored orange and green. The side chains of catalytically important residues Cys 168 and Asp248 are highlighted as space filling models, with sulfur atoms indicated in yellow and oxygen atoms indicated in red. A long α -helix connecting the N- and C-terminal domains is indicated with arrows. (B) “Side” view of the MRDI dimer, colored by the average B-factor going from blue (low B factor) to red (High B-factor). Note the higher temperature factors in both N-terminal domains suggesting flexibility in the connecting helix. Flexible loops at the tips of the N-terminal domains are labeled with their amino acid numbers. (C, D) Side and top views of the MRDI dimer, where sequence conservation is mapped to the surface. The amino acid conservation was analyzed with the Consurf server where the rapidly evolving (variable) positions are colored dark cyan, positions with average variability are colored white, and slowly evolving (conserved) positions are colored dark purple.

Fig. 3. Open-closed conformations in MTR-1-P isomerases

Top views of (A) MRDI apo form, and (B) MtnA-MTRu-1-P cocrystal. Each subunit within the dimers is colored in shades of orange and green. The catalytically important Cys and Asp residues are highlighted as space filling models. The curved arrows indicate the conformational change that the N-terminal domains would trace, in going from the open conformation, illustrated by MRDI (A), to the closed conformation illustrated by MTRu-1-P bound MtnA (B). (C) Close up and view of the active site residues in a superposition of MRDI (dark green backbone and yellow side chains) in the open conformation and MtnA (light green backbone and gray side chains) in the closed conformation. The displacement of residues in the N-terminal domain that participate in ligand binding is highlighted with arrows. (D) Proposed catalytic mechanism for the isomerization reaction catalyzed by MRDI.

Fig. 4. Surface features of MRDI and MtnA

Surface representation of (A) MRDI, (B) MtnA, and (C) MRDI-Ser283Tyr, viewed from the side that is indicated in the inset by a black arrow. Nitrogen atoms on Arg, Lys and His side chains are colored blue. Oxygen atoms on Glu and Asp side chains are colored red. Amino acids were assigned a hydrophobicity value according to the Kyte-Doolittle scale ⁽³⁶⁾, and colored from bright green for the most hydrophobic residues (Ile: 4.5) to white for residues with score less than or equal to 0 (Gly: -0.4; Arg: -4.5). Residues selected for mutation are labeled as in (A). The side chain of Tyr283 is highlighted in magenta in (C).

Fig. 5. 3D spheroid cell invasion assay for MRDI mutants

(A) Representative images of spheroids after 0-4 days in A375 cells depleted of endogenous MRDI with shRNA (KD), depleted of MRDI and expressing WT-MRDI (bpWT), and depleted of MRDI and expressing MRDI mutants (mutations indicated). (B) Extent of cell invasion into collagen, quantified as described in Materials and Methods. Values represent the mean of 4-8 independent experiments. The error bars represent standard error of the mean. (C) Western blots using anti-MRDI antibodies of naïve A375 cells (A375), A375 cells depleted of endogenous MRDI with shRNA (KD), KD and expressing MRDI by-pass wild type mutant (bpWT), or KD and expressing the indicated MRDI mutants. The left panel shows a Western blot developed using anti-HA antibody of A375 cells depleted of endogenous MRDI and expressing HA-tagged *B. subtilis* MtnA or *S. cerevisiae* Ypr118W. Because expression of Ypr118W was poor, it was excluded from analysis.

Table 1
Data Collection and Refinement Statistics

Values in parentheses represent the highest resolution shell.

Data Collection Statistics	Wild type	S283Y
Wavelength (Å)	1.54	1.00
Space Group	P2 ₁ 2 ₁ 2 ₁	P2 ₁ 2 ₁ 2 ₁
Cell Dimensions (Å)	a=44.8, b=116.6, c=136.9 = = =90°	a=44.5, b=116.0, c=135.5 = = =90°
Resolution (Å)	30.00 – 2.50 (2.59 – 2.50)	100.0 – 2.30 (2.34 – 2.30)
Unique Reflections	25,424 (2,463)	32,169 (1,576)
I/	27.2 (5.3)	22.1 (3.0)
Wilson B-factor	36.33	34.80
Redundancy	4.3 (4.1)	3.9 (3.8)
Data Completeness (%)	99.2 (98.7)	99.4 (98.5)
R _{merge} (%)	8.0 (35.9)	6.5 (41.6)
Refinement Statistics		
R _{work} (%)	17.9 (19.6)	18.0 (20.8)
R _{free} (%)	21.1 (25.7)	20.8 (24.6)
Number of non-H protein atoms	5282	5294
Number of water atoms	162	313
Number of amino acid residues	709	709
Mean B-value (Å ²)	33.6	34.0
Mean B-value protein (Å ²)	33.9	34.0
Mean B-value solvent molecules (Å ²)	26.6	34.3
Rms deviation from ideal values:		
Bond lengths (Å)	0.006	0.005
Bond angles (deg.)	1.06	0.96
Residues in Ramachandran plot:		
Most favored regions (%)	97.4	97.0
Generously allowed regions (%)	2.3	2.7
Outliers (%)	0.3	0.3